RxDoctor Payments Data

Eric Brown, MD

Nephrology · Owings Mills, MDNPI 1306980701

Payments from drug & device makers

$1,015in general payments, 2019–2025

Across 16 payments — averaging $63.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$366
  • AstraZeneca$201
  • Bayer$122
  • Novartis$121
  • Gilead$111
  • Mallinckrodt Hospital Products Inc.$88
  • plus $6 from 1 others

What the payments were for

  • Speaking & faculty fees$15015%
  • Food & beverage$82281%
  • Education$434%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)6$366
AstraZeneca(2 entities)3$201
Bayer1$122
Novartis2$121
Gilead1$111
Mallinckrodt Hospital Products Inc.1$88
Travere Therapeutics, Inc.2$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,015 in reported general payments places this provider in the 55th percentile of 285 nephrology providers in Maryland.

See all nephrology providers in Maryland

Medicare billing

Part B allowed, 2024
$308,814
Medicare patients
733
Services billed
2,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol129$157,352
JardianceEmpagliflozin39$61,935
KerendiaFinerenone16$16,822
EntrestoSacubitril/Valsartan14$11,747
DapagliflozinDapagliflozin Propanediol14$8,605
LokelmaSodium Zirconium Cyclosilicate13$8,394
Potassium Citrate ErPotassium Citrate17$2,046
Calcitriol64$1,533
Losartan Potassium86$1,177
Irbesartan23$1,070
Amlodipine Besylate74$846
Labetalol Hcl14$773
Lisinopril39$449
Spironolactone39$435
Metoprolol Succinate15$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$201$165,746142 claims
BayerKerendia$122$16,82216 claims
NovartisEntresto$121$11,74714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 285 nephrology providers in Maryland.

Other nephrology in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →